adUnits.push({
code: ‘Rpp_mundo_argentina_Nota_Interna1’,
mediaTypes: {
banner: {
sizes: (navigator.userAgent.match(/iPhone|android|iPod/i)) ? [[300, 250], [320, 460], [320, 480], [320, 50], [300, 100], [320, 100]] : [[300, 250], [320, 460], [320, 480], [320, 50], [300, 100], [320, 100], [635, 90]]
}
},
bids: [{
bidder: ‘appnexus’,
params: {
placementId: ‘14149971’
}
},{
bidder: ‘rubicon’,
params: {
accountId: ‘19264’,
siteId: ‘314342’,
zoneId: ‘1604128’
}
},{
bidder: ‘amx’,
params: {
tagId: ‘MTUybWVkaWEuY29t’
}
},{
bidder: ‘oftmedia’,
params: {
placementId: navigator.userAgent.match(/iPhone|android|iPod/i) ? ‘22617692’: ‘22617693’
}
}]
});
Argentina called on volunteers to conduct the last phase of a phase 2/3 clinical trial of a COVID-19 vaccine developed by local scientists, ARVAK Cecilia Griersonand awaits its approval in the middle of the year.
researcher Juliana Cassataro clarified that the safety and immunogenicity of three ARVAC formulations, including the bivalent version against omicron, will be evaluated at this stage.
The scientist overtook the radio Province AM1270 that “if by May” we can “complete the recruitment of volunteers”, we will have “results in June” and the National Drugs, Food and Medical Technology Administration “can approve vaccine”, which will then be bought by the state.
ARVAC Vaccine Cecilia Grierson – baptized in the name of the first Argentine doctor who lived between 1859 and 1934 – developed jointly by the National Council for Scientific and Technical Research (Conicet), the National University of San Martin (Unsam) and the private laboratory of Pablo Cassar.
According to the Ministry of Science, Technology and Innovation, the results of the first stage of the study showed that the ARVAK vaccine is safe, and the preliminary indicators of the immune response are encouraging.
Argentina it is now moving on to get the results, which will be submitted to Anmat for approval as a booster vaccine.
Phase 2/3 consists of two phases: the first, which is ongoing, administers the vaccine to 232 people, and the second begins with the recruitment of 1,782 people for the ARVAC formula.
Vaccine protection
The Argentine vaccine is designed to protect against SARS-CoV-2 variants circulating in the region, and Cassataro added on Tuesday that the vaccine “responds to Omicron V1 and V5” and that while “covid is changing” it will have “a platform for modification, like it does with the flu.”
The head of the group producing the Argentine serum argued that the creation of a vaccine “is a medium-term and long-term project, and Argentina has long had the resources for this.”
He argued that the cost of other developments “on an economic level is completely different”, because “it is local production”.
And appreciated “that all covid vaccines are tested” in Argentinawhich “demonstrates” that it has “excellent clinical investigators” and “a pharmaceutical industry comparable only to Brazil in the region, as well as investment in education, science and technology” (EFE).
Source: RPP
I’m a passionate and motivated journalist with a focus on world news. My experience spans across various media outlets, including Buna Times where I serve as an author. Over the years, I have become well-versed in researching and reporting on global topics, ranging from international politics to current events.